
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
VJHemOnc Podcast
00:00
Emerging Mutations and Challenges in AML Treatment
This chapter discusses the use of fluoro-lipoatmin and ongoing studies on doublet versus triplet salvage therapies in AML treatment. It also highlights the challenge of targeting emergent mutations, particularly MAP/RAS pathway mutations, due to the lack of effective RAS inhibitors.
Play episode from 43:29
Transcript


